"Pulmonary Arterial Hypertension (PAH) Treatment Market to Exhibit Healthy Growth during the Forecast Period between 2018 & 2026"
The global pulmonary arterial hypertension (PAH) treatment market accounted for a value of US$ 7,802.9 Mn in 2017 and expected to attain US$ 14,642.1 Mn by 2026. Drivers accountable for the market growth are worldwide growing elderly population along with increasing prevalence of pulmonary arterial hypertension due to rising risk factors such as connective tissue disorders, human immunodeficiency virus (HIV) infection, chronic liver diseases, lung diseases, sedentary lifestyle, and other idiopathic conditions. Furthermore, increasing launches of novel drugs & treatment therapies, favorable initiatives by various governments, and rising spending on healthcare is expected to foster the market growth over the forecast period. According to the European Respiratory Society (ERS), the global prevalence of PAH is ranging from 10 to 52 cases per million and estimated to be in the range of 100,000–200,000 every year. The Centers for Disease Control and Prevention (CDC) reported that the disease affects 1 to 2 people in every 1.0 Mn over the U.S. and Europe. This medical condition is more common in older women and can affect men as well. A data published by the National Hospital Discharge Survey and National Vital Statistics System (NVSS) revealed that death rates from PAH increased 2.5% per year for women and 0.9% per year for men between 2001 and 2010. The World Health Organization (WHO) reported that global aging population would rise from 841.0 Mn in 2013 to 962.3 Mn in 2017 to cross 2.0 Bn by 2050.
Market Synopsis
Get a sample copy for more information
"The Endothelin Receptor Antagonists Segment is expected to continue the Dominance over the forecast period from 2018 to 2026"
On the basis of drug class, the endothelin receptor antagonists segment dominated the market in 2017 as the endothelin receptor antagonism has emerged as a significant therapeutic strategy which acts as the potential pathogenetic in the development & progression of pulmonary vasculopathy during pulmonary arterial hypertension treatment. Few oral (ERAs) are approved by the U.S. Food and Drug Administration (US FDA) for class III and IV patients suffering from pulmonary arterial hypertension. Letairis/Volibris (ambrisentan), Opsumit (macitentan), and Tracleer (bosentan) are the leading drugs for PAH treatment that are supporting the dominance of ERAs.
Get a sample copy for more information
"Pipeline Analysis — the Presence of Promising Drug Candidates in Clinical Pipeline Would be the Game Changers of Market in the Near Future"
Lung Biotechnology PBC (a wholly-owned subsidiary of United Therapeutics Corporation) and Toray Industries, Inc. completed a Phase II extension trial for Beraprost Sodium 314d Modified Release (BPS-314d-MR), a reformulated single isomer of beraprost in PAH patients in the U.S., Ireland, and Belgium. Additionally, on 3rd September 2018, Lung Biotechnology PBC planned for a Phase III trial for BPS-314d-MR that would be initiated in December 2018. Moreover, Liquidia Technologies, Inc. and Nuventra, Inc. are recruiting a Phase III clinical trial for LIQ861 (inhaled treprostinil) to evaluate the long-term safety and tolerability of the drug in PAH patients. These pipeline drugs are expected to significantly impact on market by the end of 2020.
"North America Holds Dominant Position due to the Presence of Supportive Infrastructure for Development and Distribution of High Quality Therapies"
North America held the highest market share in 2017 due to the presence of major market players & well-established healthcare infrastructure, rising prevalence of lung disorders coupled with increasing US FDA approvals for drugs & early market initiation of the PAH treatment drugs. On the other hand, growing elderly population base along with rising burden of causative diseases including scleroderma, lupus, cirrhosis of the liver, and HIV infection; and improving healthcare system in China, India, and Japan are expected to support the lucrative CAGR of Asia Pacific over the forecast period.
Get a sample copy for more information
"The Presence of International Market Participants Makes Market Penetration Challenging for New Entrants"
Major players in this space are GlaxoSmithKline plc; Pfizer Inc.; Gilead Sciences, Inc.; Novartis International AG; Bayer AG; Merck KGaA; Bristol-Myers Squibb Company; United Therapeutics Corporation; Actelion Pharmaceuticals Ltd; Reata Pharmaceuticals, Inc.; Toray Industries, Inc.; Liquidia Technologies, Inc.; and Nuventra Pharma Sciences. Companies are focusing on novel drug approvals & launches, mergers & acquisitions, partnerships, and collaboration strategies to gain an impetus in the market. For instance, in November 2015, GlaxoSmithKline plc received an approval from European Commission (EC) for Volibris (ambrisentan) in the treatment of pulmonary arterial hypertension in adult patients of WHO functional class (FC) II to III. Pfizer Inc.’s REVATIO, the capsules containing sildenafil (phosphodiesterase-5 inhibitor) are used in the treatment of adult patients with PAH.
Historical & Forecast Period
This study report represents analysis for each segment from 2016 to 2026 considering 2017 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2018 to 2026.
Report Scope by Segments
Pulmonary arterial hypertension treatment market covers qualitative & quantitative analysis of current market dynamics. The report involves all-inclusive information on the global pulmonary arterial hypertension treatment market by segmenting the market on the basis of drug class and geography. This report will guide industry investors & associations, pharmaceutical industry participants, venture capitalists, suppliers & distributors of PAH drugs, medical research institutes, research & consulting firms, and healthcare professionals (HCPs) in decision-making and strategizing the market position.
| ATTRIBUTE |
DETAILS |
| Research Period |
2016-2026 |
| Base Year |
2017 |
| Forecast Period |
2018-2026 |
| Historical Year |
2016 |
| Unit |
USD Million |
| Segmentation |
Drug Class Segment (2016–2026; US$ Mn)
• Endothelin Receptor Antagonists (ERAs)
• Vasodilators
• Phosphodiesterase-5 (PDE-5) inhibitors
• Soluble Guanylate Cyclase (sGC) Stimulators
• Calcium Channel Blockers (CCBs)
• Others (anticoagulants, diuretics, and cardiac glycosides)
• Pipeline Analysis
o Phase III (Forecast till 2026) (US$ Mn)
Beraprost Sodium 314d Modified Release (BPS-314d-MR)
LIQ861 Inhaled Treprostinil
o Phase II & I (Tabular Format)
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (United States and Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of MEA)
|
The current report also incorporates qualitative & quantitative analysis of market variables such as key market drivers, restraints, opportunities, and trends which convey better market information of the entire pulmonary arterial hypertension treatment. Additionally, the report also comprises a graphical illustration of the competitive landscape based on their market initiatives & strategies, product portfolio, financial information, and key developments. Major market players profiled in this study report are GlaxoSmithKline plc; Pfizer Inc.; Gilead Sciences, Inc.; Novartis International AG; Bayer AG; Merck KGaA; Bristol-Myers Squibb Company; United Therapeutics Corporation; Actelion Pharmaceuticals Ltd; Reata Pharmaceuticals, Inc.; Toray Industries, Inc.; Liquidia Technologies, Inc.; and Nuventra Pharma Sciences
Key questions answered in this report
- What are the current market trends and dynamics in the pulmonary arterial hypertension treatment market and valuable opportunities for emerging players?
- Which drug class contributes to the maximum market share?
- Which drug class accounts for the fastest CAGR during the forecast period?
- What is the effect of pipeline drugs on the market dynamics in the future?
- What is the impact of high cost pulmonary arterial hypertension treatment drugs on the market?
- Are low and middle-income economies investing in the pulmonary arterial hypertension treatment market?
- What is the market trend and dynamics in emerging markets such as Latin America and Middle East & Africa?
